NEKTAR THERAPEUTICS
NEKTAR THERAPEUTICS
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 39 | 150 | 15 | 41 | 43 | 39 | 44 | 30 | 28 | 49 | 35 | 65 | |||||
Available For Sale Securities Debt Securities Curr… | 645 | 419 | 231 | 229 | 133 | 180 | 211 | 214 | 243 | 241 | 268 | 308 | |||||
Accounts Receivable Net Current | - | - | - | - | - | - | 0 | 0 | 1 | 4 | 1 | 2 | |||||
Other Assets Current | 55 | 20 | 21 | 11 | 11 | 11 | 6 | 9 | 8 | 11 | 10 | 9 | |||||
Assets Of Disposal Group Including Discontinued Op… | - | - | - | - | - | - | - | 33 | - | - | - | - | |||||
Inventory Net | - | - | 0 | - | - | - | 0 | 0 | 14 | 16 | 16 | 15 | |||||
Assets Current | 739 | 589 | 266 | 281 | 187 | 230 | 261 | 286 | 295 | 320 | 331 | 399 | |||||
Available For Sale Securities Debt Securities Nonc… | 339 | 163 | 0 | 0 | 0 | 2 | 14 | 5 | 19 | 37 | 26 | - | |||||
Property Plant And Equipment Net | - | - | 2 | 3 | 3 | 3 | 3 | 4 | 15 | 17 | 19 | 20 | |||||
Operating Lease Right Of Use Asset | - | - | 3 | 7 | 8 | 8 | 8 | 9 | 9 | 17 | 18 | 19 | |||||
Goodwill | - | - | - | - | - | - | - | - | - | - | 0 | 0 | |||||
Equity Method Investments | - | - | 3 | 5 | 5 | 8 | 12 | - | - | - | - | - | |||||
Other Assets Noncurrent | 17 | 11 | 6 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | |||||
Assets | 1,095 | 763 | 280 | 301 | 208 | 256 | 304 | 308 | 343 | 396 | 398 | 442 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Accounts Payable Current | 25 | 10 | 11 | 16 | 14 | 18 | 12 | 9 | 6 | 9 | 10 | 3 | |||||
Accrued Liabilities Current | 23 | 25 | 22 | 29 | 35 | 31 | 30 | 32 | 30 | 24 | 22 | 30 | |||||
Operating Lease Liability Current | 23 | 23 | 20 | 22 | 22 | 22 | 20 | 22 | 21 | 19 | 19 | 19 | |||||
Liabilities Of Disposal Group Including Discontinu… | - | - | - | - | - | - | - | 5 | - | - | - | - | |||||
Liabilities Current | 71 | 58 | 54 | 66 | 71 | 71 | 61 | 68 | 57 | 52 | 51 | 52 | |||||
Operating Lease Liability Noncurrent | 56 | 61 | 65 | 70 | 74 | 78 | 83 | 87 | 91 | 95 | 99 | 102 | |||||
Other Liabilities Noncurrent | 8 | 8 | 9 | 5 | 6 | 7 | 7 | 7 | 8 | 4 | 5 | 5 | |||||
Liabilities | 192 | 187 | 191 | 216 | 232 | 243 | 243 | 259 | 264 | 269 | 267 | 283 | |||||
Stockholders Equity | |||||||||||||||||
Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital Common Stock | 4,751 | 4,382 | 3,850 | 3,809 | 3,667 | 3,664 | 3,660 | 3,655 | 3,650 | 3,644 | 3,608 | 3,601 | |||||
Treasury Stock Value | - | - | - | 0 | -3 | -3 | -3 | -3 | -3 | -3 | - | - | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -2 | -1 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | -6 | |||||
Retained Earnings Accumulated Deficit | -3,846 | -3,805 | -3,760 | -3,724 | -3,689 | -3,647 | -3,596 | -3,603 | -3,566 | -3,514 | -3,477 | -3,435 | |||||
Stockholders Equity | 903 | 576 | 90 | 85 | -24 | 14 | 61 | 49 | 80 | 127 | 131 | 159 | |||||
Liabilities And Stockholders Equity | 1,095 | 763 | 280 | 301 | 208 | 256 | 304 | 308 | 343 | 396 | 398 | 442 | |||||
Gannet Bio Chem | - | - | 0 | - | - | - | 12 | - | - | - | - | - | |||||
Related Party | - | 0 | 0 | -1 | 0 | 0 | 0 | - | - | - | 0 | - | |||||
Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | 0 | - | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 390 | 390 | 390 | 390 | 390 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | |||||
Common Stock Shares Issued | 34 | 29 | 20 | 20 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | |||||
Shares Outstanding | 20 | 20 | 20 | 20 | 12 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | |||||
Treasury Stock Common Shares | - | - | 0 | 0 | 1 | 8 | 1 | 8 | 8 | 1 | 0 | - | |||||
Stockholders Equity Note Stock Split Conversion Ra… | - | 0 | - | - | - | 0 | 0 | 0 | 0 | - | - | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -20.77% | -22.27% | -13.63% | - | - | - | - | - | - | - | - | - |
| 2025 | 22.03% | 191.07% | 182.49% | 29.49% | 153.69% | 160.62% | 16.51% | -20.51% | -33.70% | 5.11% | 18.03% | -11.43% |
| 2024 | -27.84% | -29.55% | -21.59% | 15.32% | 5.41% | 18.92% | -18.57% | -32.14% | -37.14% | -38.89% | -16.67% | -20.00% |
| 2023 | - | - | - | - | - | - | 6.00% | 12.00% | 2.00% | 5.68% | 50.00% | 86.36% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 10.42 | 10.21 | 4.97 | 4.24 | 2.61 | 3.24 | 4.26 | 4.24 | 5.15 | 6.10 | 6.45 | 7.66 | |||||
| Quick Ratio | 10.42 | 10.21 | 4.97 | 4.24 | 2.61 | 3.24 | 4.26 | 4.24 | 4.90 | 5.79 | 6.14 | 7.37 | |||||
| Working Capital | 668.42M | 531.33M | 212.73M | 215.02M | 115.18M | 158.98M | 199.89M | 218.90M | 237.86M | 267.43M | 279.43M | 346.91M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.21 | 0.32 | 2.12 | 2.54 | -9.57 | 17.65 | 4.00 | 5.30 | 3.31 | 2.13 | 2.04 | 1.77 | |||||
| Debt Ratio | 0.18 | 0.25 | 0.68 | 0.72 | 1.12 | 0.95 | 0.80 | 0.84 | 0.77 | 0.68 | 0.67 | 0.64 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.08 | 0.11 | 0.19 | 0.21 | 0.27 | 0.27 | 0.28 | 0.25 | 0.22 | 0.19 | 0.16 | 0.14 | |||||
| Days Sales Outstanding TTM | - | - | - | - | - | - | - | - | 4.96 | 13.38 | 14.55 | 28.40 | |||||
| Receivables Turnover TTM | - | - | - | - | - | - | - | - | 73.61 | 27.27 | 25.08 | 12.85 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -4.75 | -6.39 | -9.73 | -6.37 | -8.68 | -9.46 | -8.68 | -12.06 | -12.72 | -13.54 | -21.78 | -23.12 | |||||
| Free Cash Flow Per Share TTM | -7.08 | -8.24 | -12.37 | -10.05 | -13.21 | -12.67 | -12.92 | -12.75 | -12.60 | -14.56 | -15.27 | -16.09 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | - | - | - | - | - | - | 68.82% | 67.80% | 59.22% | 60.91% | 62.53% | 62.93% | |||||
| Operating Profit Margin TTM | -257.80% | -241.98% | -253.66% | -156.69% | -134.47% | -131.01% | -106.88% | -164.34% | -175.59% | -182.33% | -292.59% | -320.24% | |||||
| Net Profit Margin TTM | -287.84% | -284.18% | -297.07% | -192.87% | -163.17% | -152.49% | -120.86% | -180.70% | -190.09% | -195.02% | -306.31% | -332.73% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | -27.15% | -36.24% | -43.89% | -32.79% | -19.56% | -3.24% | 9.22% | 5.53% | 6.17% | 1.51% | -2.10% | -7.13% | |||||
| Net Income Growth (1Y) | 28.51% | 18.83% | 37.92% | -28.26% | -30.95% | -24.34% | -56.91% | -42.69% | -42.30% | -57.61% | -25.03% | -35.34% | |||||
| EPS Growth (1Y) | -45.23% | -32.44% | 12.09% | -47.18% | -31.77% | -30.12% | -60.17% | -47.82% | -47.57% | -58.89% | -26.15% | -36.28% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -14.69 | -11.26 | -4.35 | -8.93 | -2.98 | -1.08 | -1.61 | -1.62 | -1.46 | -1.03 | -0.39 | -0.39 | |||||
| P/B TTM | 2.56 | 3.09 | 7.94 | 12.67 | -15.04 | 10.44 | 3.15 | 5.56 | 3.25 | 1.43 | 0.81 | 0.72 | |||||
| P/S TTM | 42.27 | 31.99 | 12.91 | 17.22 | 4.86 | 1.64 | 1.94 | 2.92 | 2.78 | 2.01 | 1.18 | 1.30 | |||||
| Market Cap | 2.31B | 1.78B | 713.30M | 1.08B | 364.02M | 143.45M | 191.27M | 272.02M | 258.94M | 181.20M | 106.45M | 114.30M | |||||
| Enterprise Value | 2.27B | 1.63B | 698.19M | 1.04B | 321.03M | 104.55M | 147.01M | 241.91M | 231.00M | 132.56M | 71.18M | 49.38M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -234.03M | -203.94M | -208.68M | -190.35M | -186.07M | -178.19M | -177.18M | -177.82M | -175.37M | -189.17M | -193.47M | -204.40M | |||||
| Net Debt | -39.27M | -149.58M | -15.12M | -41.03M | -42.99M | -38.89M | -44.25M | -30.11M | -27.94M | -48.64M | -35.28M | -64.92M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| PEG Ratio | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| EV Revenue TTM | |||||||||||||||||
| EV FCF TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
NEKTAR THERAPEUTICS (NKTR) — SEC Financial Statements & Analysis
NEKTAR THERAPEUTICS (NKTR) is a pharmaceutical preparations company, incorporated in DE. NEKTAR THERAPEUTICS trades on Nasdaq as: NKTR. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), NEKTAR THERAPEUTICS reported a -27.15% year-over-year revenue growth, a Gross Profit Margin of 68.82% (TTM), a Debt-to-Equity ratio of 0.21x, a Price-to-Sales (P/S) ratio of 42.27x (TTM), a Price-to-Book (P/B) ratio of 2.56x (TTM), at a market cap of $2.31B. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- -27.15%
- Gross Profit Margin TTM
- 68.82%
- Debt To Equity
- 0.21x
- P/S TTM
- 42.27x
- P/B TTM
- 2.56x
- Market Cap
- $2.31B
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is NEKTAR THERAPEUTICS in?
NEKTAR THERAPEUTICS (NKTR) operates in the Pharmaceutical Preparations industry.
What is NKTR's market cap?
NEKTAR THERAPEUTICS (NKTR) has a market capitalization of $2.31B as of 2026-06-30.
What exchange does NKTR trade on?
NEKTAR THERAPEUTICS (NKTR) trades on the Nasdaq.
Where is NEKTAR THERAPEUTICS incorporated?
NEKTAR THERAPEUTICS is incorporated in DE.